The S&P 500 Futures are rebounding after they closed in the red on Friday.
Later today, the Federal Reserve Bank of Chicago will post October National Activity Index (0.27 expected). Research firm Markit will publish preliminary readings of November Manufacturing PMI (52.5 expected) and November Services PMI (55.8 expected).
European indices are on the upside. AstraZeneca announced that its candidate vaccine developed with Oxford University is 70% effective on average. Research firm Markit has published preliminary readings of November Manufacturing PMI for the eurozone at 53.6 (vs 54.2 expected), for Germany at 57.9 (vs 57.3 expected), for France at 49.1 (vs 49.9 expected) and for the U.K. at 55.2 (vs 51.6 expected). Also, the preliminary readings of November Services PMI for the eurozone was published at 41.3 (vs 44.1 expected), at 46.2 for Germany (vs 47.5 expected), at 38.0 for France (vs 39.0 expected) and at 45.8 for the U.K. (vs 46.0 expected).
Asian indices closed slightly on the upside except the Hong Kong HSI. The Japanese Nikkei was closed for holiday.
WTI Crude Oil remains strong. The total number of rotary rigs in the U.S. slipped to 310 as of November 20 from 312 in the prior week, while rigs in Canada rose to 101 from 89, according to Baker Hughes.
U.S indices closed down on Friday, pressured by Banks (-1.15%), Consumer Services (-1.14%) and Software & Services (-1.13%) sectors.
Approximately 90% of stocks in the S&P 500 Index were trading above their 200-day moving average and 81% were trading above their 20-day moving average. The VIX Index rose 0.59pt (+2.55%) to 23.7 and WTI Crude Oil jumped $0.5 (+1.19%) to $42.4 at the close.Gold and U.S dollar consolidate as investors favor riskier assets currently.
Gold fell 3.86 dollars (-0.21%) to 1867.13 dollars.
The dollar index declined 0.34pt to 92.056.
U.S. Equity Snapshot
Regeneron Pharmaceuticals (REGN), a biotechnology company, reported that its REGEN-COV2, an antibody cocktail for Covid-19, has received Emergency Use Authorization from the U.S. Food and Drug Administration. The company said it "now expects to have REGEN-COV2 treatment doses ready for approximately 80,000 patients by the end of November, approximately 200,000 patients by the first week of January, and approximately 300,000 patients in total by the end of January 2021".
Source: TradingView, GAIN CapitalTesla (TSLA)'s, the electric-vehicle maker, price target was raised to 560 dollars from 500 dollars at Wedbush.
Netflix (NFLX)'s, the video streaming service, target price was raised to 628 dollars from 615 dollars at JPMorgan.
Disclaimer: GAIN Capital UK Limited (trading as "Forex.com") is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, Forex.com does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by Forex.com or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although Forex.com is not specifically prevented from dealing before providing this material, Forex.com does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
For further details see our full non-independent research disclaimer and quarterly summary.